Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

Ionis highlighted the drug's sustained efficacy and safety profile, which could make it the prophylactic treatment of choice for those living with HAE. Donidalorsen targets prekallikrein (PKK), a ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. While preparing to go head to head in a rare disease market, the companies have signed up ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

In the FCS market, Ionis aims to leverage a first-mover advantage with Tryngolza, while in HAE, the company anticipates a favorable market position following recent setbacks faced by competitors.

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS) and ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

CARLSBAD, Calif., March 26, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: A live ...

Kenneth Newman, M.D., senior vice president and head of clinical development at Ionis, commented on the significance of the findings. He emphasized the need for an effective and well-tolerated ...

2. Tryngolza: Approved for FCS, this drug represents Ionis’s entry into the rare lipid disorder market. A Phase III study for severe hypertriglyceridemia (sHTG) is expected to yield data in the second ...